Merck & Co Inc reported higher-than-expected second-quarter profit on Tuesday, powered by strong demand for its cancer immunotherapy Keytruda and vaccines, sending its shares up 3% in early trading.
Source:: Reuters – Business News
Newswire
- [ January 23, 2025 ] Kopin (NASDAQ: KOPN) to Showcase Newly Advanced Near-to-Eye Microdisplays and Application-Specific Optical Solutions at AR/VR/MR 2025 Newsmakers
- [ January 23, 2025 ] Hepion Pharmaceuticals (NASDAQ:HEPA) Announces $9.0 Million Public Offering Newsmakers
- [ January 23, 2025 ] N2OFF (NASDAQ: NITO) and Solterra Join Forces to Exclusively Co-Develop the Solar PV Market in Albania Newsmakers
- [ January 16, 2025 ] United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s (NASDAQ: BMRA)Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer Newsmakers
- [ January 15, 2025 ] Vision Marine Technologies (NASDAQ:VMAR) Files Patent Application for Proprietary Battery Encryption System Newsmakers
- [ January 15, 2025 ] Safe & Green Holdings (NASDAQ: SGBX)Announces LOI for Transformative Acquisition of Olenox and Machfu.com Newsmakers
- [ January 14, 2025 ] Castellum (NYSE: CTM) Announces the Award of a $3.2 million Contract to its Specialty Systems, Inc. Subsidiary Newsmakers
- [ January 14, 2025 ] Richtech Robotics (NASDAQ: RR) to Showcase Latest Service Robotics Innovations at CES 2025, Featuring AI-Driven Scorpion Robot and New Delivery Robots Newsmakers
- [ January 14, 2025 ] Firefly Neuroscience (NASDAQ: AIFF) Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform Newsmakers
- [ January 14, 2025 ] Nature’s Miracle Holding, Inc. (NASDAQ: NMHI) Announces Up to $29.7 Million Financing Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.